| 19.21 -0.57 (-2.88%) | 09-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 26.99  |
1-year : | 29.84 |
| Resists | First : | 23.11 |
Second : | 25.55 |
| Pivot price | 22.25 |
|||
| Supports | First : | 19.17 |
Second : | 15.94 |
| MAs | MA(5) : | 20.85 |
MA(20) : | 22.53 |
| MA(100) : | 24.17 |
MA(250) : | 20.41  |
|
| MACD | MACD : | -1.2 |
Signal : | -0.9 |
| %K %D | K(14,3) : | 3.3 |
D(3) : | 11 |
| RSI | RSI(14): 28.7 |
|||
| 52-week | High : | 30.98 | Low : | 11.81 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BCAX ] has closed below the lower bollinger band by 7.6%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 13.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 19.88 - 20.04 | 20.04 - 20.15 |
| Low: | 18.84 - 19.01 | 19.01 - 19.13 |
| Close: | 18.98 - 19.25 | 19.25 - 19.43 |
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
Fri, 18 Sep 2026
Bicara Therapeutics Inc. - Common Stock (Nasdaq:BCAX) Detailed Stock Data - The Chronicle-Journal
Thu, 10 Sep 2026
BCAX Form 4 Filings - Bicara Therapeutics Inc. SEC Form 4 - Stock Titan
Thu, 10 Sep 2026
Bicara interim CEO sells 17,500 shares after option exercise | BCAX Insider Trading - Stock Titan
Thu, 03 Sep 2026
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Mon, 17 Aug 2026
BCAX Stock Price and Chart — NASDAQ:BCAX - TradingView
Tue, 11 Aug 2026
Bicara Therapeutics Inc. Common Stock Q2 2026 Earnings Call Summary - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 66 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 10 (%) |
| Held by Institutions | 107.7 (%) |
| Shares Short | 10,460 (K) |
| Shares Short P.Month | 9,320 (K) |
| EPS | -3.07 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.11 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -26.2 % |
| Return on Equity (ttm) | -41.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -135 (M) |
| Levered Free Cash Flow | -77 (M) |
| PE Ratio | -6.26 |
| PEG Ratio | 0 |
| Price to Book value | 2.7 |
| Price to Sales | 0 |
| Price to Cash Flow | -9.43 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|